Literature DB >> 32997485

Binding Modes and Selectivity of Cannabinoid 1 (CB1) and Cannabinoid 2 (CB2) Receptor Ligands.

Jing-Fang Yang, Alexander H Williams, Narsimha R Penthala1, Paul L Prather2, Peter A Crooks1, Chang-Guo Zhan.   

Abstract

The cannabinoid (CB) receptors (CB1R and CB2R) represent a promising therapeutic target for several indications such as nociception and obesity. The ligands with nonselectivity can be traced to the high similarity in the binding sites of both cannabinoid receptors. Therefore, the need for selectivity, potency, and G-protein coupling bias has further complicated the design of desired compounds. The bias of currently studied cannabinoid agonists is seldom investigated, and agonists that do exhibit bias are typically nonselective. However, certain long-chain endocannabinoids represent a class of selective and potent CB1R agonists. The binding mode for this class of compounds has remained elusive, limiting the implementation of its binding features to currently studied agonists. Hence, in the present study, the binding poses for these long-chain cannabinoids, along with other interesting ligands, with the receptors have been determined, by using a combination of molecular docking and molecular dynamics (MD) simulations along with molecular mechanics-Poisson-Boltzmann surface area (MM-PBSA) binding free energy calculations. The binding poses for the long-chain cannabinoids implicate that a site surrounded by the transmembrane (TM)2, TM7, and extracellular loop (ECL)2 is vital for providing the long-chain ligands with the selectivity for CB1R, especially I267 of CB1R (corresponding to L182 of CB2R). Based on the obtained binding modes, the calculated relative binding free energies and selectivity are all in good agreement with the corresponding experimental data, suggesting that the determined binding poses are reasonable. The computational strategy used in this study may also prove fruitful in applications with other GPCRs or membrane-bound proteins.

Entities:  

Keywords:  Cannabinoid receptor; drug design strategy; endocannabinoid; modeling; selectivity

Mesh:

Substances:

Year:  2020        PMID: 32997485      PMCID: PMC7756905          DOI: 10.1021/acschemneuro.0c00551

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  61 in total

1.  The Amber biomolecular simulation programs.

Authors:  David A Case; Thomas E Cheatham; Tom Darden; Holger Gohlke; Ray Luo; Kenneth M Merz; Alexey Onufriev; Carlos Simmerling; Bing Wang; Robert J Woods
Journal:  J Comput Chem       Date:  2005-12       Impact factor: 3.376

2.  Cryo-EM Structure of the Human Cannabinoid Receptor CB2-Gi Signaling Complex.

Authors:  Changrui Xing; Youwen Zhuang; Ting-Hai Xu; Zhiwei Feng; X Edward Zhou; Maozi Chen; Lei Wang; Xing Meng; Ying Xue; Junmei Wang; Heng Liu; Terence Francis McGuire; Gongpu Zhao; Karsten Melcher; Cheng Zhang; H Eric Xu; Xiang-Qun Xie
Journal:  Cell       Date:  2020-01-30       Impact factor: 41.582

Review 3.  Current evidence of cannabinoid-based analgesia obtained in preclinical and human experimental settings.

Authors:  J Lötsch; I Weyer-Menkhoff; I Tegeder
Journal:  Eur J Pain       Date:  2017-11-21       Impact factor: 3.931

4.  The effect of multiple simulation parameters on MM/PBSA performance for binding affinity prediction of CB1 cannabinoid receptor agonists and antagonists.

Authors:  Jason S E Loo; Amelia Y Y Yong; Yen Nee Yong
Journal:  Chem Biol Drug Des       Date:  2020-06-25       Impact factor: 2.817

5.  The difference between the CB(1) and CB(2) cannabinoid receptors at position 5.46 is crucial for the selectivity of WIN55212-2 for CB(2).

Authors:  Z H Song; C A Slowey; D P Hurst; P H Reggio
Journal:  Mol Pharmacol       Date:  1999-10       Impact factor: 4.436

6.  Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1).

Authors:  C J Hillard; S Manna; M J Greenberg; R DiCamelli; R A Ross; L A Stevenson; V Murphy; R G Pertwee; W B Campbell
Journal:  J Pharmacol Exp Ther       Date:  1999-06       Impact factor: 4.030

7.  Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor "hybrid" ligands.

Authors:  V Di Marzo; T Bisogno; L De Petrocellis; I Brandi; R G Jefferson; R L Winckler; J B Davis; O Dasse; A Mahadevan; R K Razdan; B R Martin
Journal:  Biochem Biophys Res Commun       Date:  2001-02-23       Impact factor: 3.575

8.  The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain.

Authors:  U Herzberg; E Eliav; G J Bennett; I J Kopin
Journal:  Neurosci Lett       Date:  1997-01-17       Impact factor: 3.046

9.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility.

Authors:  Garrett M Morris; Ruth Huey; William Lindstrom; Michel F Sanner; Richard K Belew; David S Goodsell; Arthur J Olson
Journal:  J Comput Chem       Date:  2009-12       Impact factor: 3.376

Review 10.  Cannabinoids and Pain: New Insights From Old Molecules.

Authors:  Sonja Vučković; Dragana Srebro; Katarina Savić Vujović; Čedomir Vučetić; Milica Prostran
Journal:  Front Pharmacol       Date:  2018-11-13       Impact factor: 5.810

View more
  3 in total

1.  Synthesis, Molecular Pharmacology, and Structure-Activity Relationships of 3-(Indanoyl)indoles as Selective Cannabinoid Type 2 Receptor Antagonists.

Authors:  Harvey F Fulo; Amal Shoeib; Christian V Cabanlong; Alexander H Williams; Chang-Guo Zhan; Paul L Prather; Gregory B Dudley
Journal:  J Med Chem       Date:  2021-04-23       Impact factor: 7.446

2.  Fast Prediction of Binding Affinities of SARS-CoV-2 Spike Protein and Its Mutants with Antibodies through Intermolecular Interaction Modeling-Based Machine Learning.

Authors:  Alexander H Williams; Chang-Guo Zhan
Journal:  J Phys Chem B       Date:  2022-07-11       Impact factor: 3.466

3.  Structural Insights into β-arrestin/CB1 Receptor Interaction: NMR and CD Studies on Model Peptides.

Authors:  Paula Morales; Marta Bruix; M Angeles Jiménez
Journal:  Int J Mol Sci       Date:  2020-10-30       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.